SEC Form 4 · accession 0000908662-16-000384
ENANTA PHARMACEUTICALS INC · ENTA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Yat Sun Or
Officer — Chief Scientific Officer
Period of report
Jan 9, 2016
Accepted (ET)
Jan 11, 2016 · 4:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001177648
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $14.00 | Jan 9, 2016 | A | 3,478 | A | Jan 9, 2016 | Mar 20, 2023 | Common Stock | 3,478 | 3,478 | D |
Explanation of responses
- F1On March 20, 2013, the reporting person was granted an option to purchase 41,763 shares of common stock, which does not become reportable on Form 4 until the option becomes exercisable. The option becomes exercisable in up to nine installments, six of which are installments of 8.33% of the shares and three of which are installments of 16.67% of the shares, based on ENTA's achievement of certain clinical milestones with respect to three or more programs that progress to clinical development. Previously, on January 10, 2014, a clinical milestone for one 8.33% installment was achieved, resulting in the vesting of the option as to 3,478 shares. On January 9, 2016, a clinical milestone for a second 8.33% installment was achieved, resulting in the vesting of the option as to an additional 3,478 shares.